Opioids are widely used for treating different types of pains, but overuse and abuse 2 of prescription opioids have led to opioid epidemic in the United States. Besides 3 analgesic effects, chronic use of opioid can also cause tolerance, dependence, 4 and even addiction. Effective treatment of opioid addiction remains a big challenge 5 today. Studies on addictive effects of opioids focus on striatum, a main component 6 in the brain responsible for drug dependence and addiction. Some transcription 7 regulators have been associated with opioid addiction, but relationship between 8 analgesic effects of opioids and dependence behaviors mediated by them at the 9 molecular level has not been thoroughly investigated. In this paper, we developed 10 a new computational strategy that identifies novel targets and potential therapeutic 11 molecular compounds for opioid dependence and addiction. We employed several 12 statistical and machine learning techniques and identified differentially expressed 13 genes over time which were associated with dependence-related behaviors after 14 exposure to either morphine or heroin, as well as potential transcription regulators 15 that regulate these genes, using time course gene expression data from mouse 16 striatum. Moreover, our findings revealed that some of these dependence-17 associated genes and transcription regulators are known to play key roles in 18 opioid-mediated analgesia and tolerance, suggesting that an intricate relationship 19 between opioid-induce pain-related pathways and dependence may develop at an 20 early stage during opioid exposure. Finally, we determined small compounds that 21 can potentially target the dependence-associated genes and transcription 22 transcription regulators. We also built a database for the genes, transcription 45 regulators, and small compounds, which is available at http://daportals.org. 46 47 gene targets as well as potential therapeutic interventions for treating opioid 126 dependence and addiction. 127 128
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Fax: 412-268-2977 29 Email: weiwu2@cs.cmu.edu 30 regulators. These compounds may facilitate development of effective therapy for 23 opioid dependence and addiction. We also built a database (http://daportals.org) 24 for all opioid-induced dependence-associated genes and transcription regulators 25 that we discovered, as well as the small compounds that target those genes and 26 transcription regulators. 27 28 Author summary 29 Opioids are widely used to treat pain in the clinics, however, overuse and abuse 30 of prescription opioids in the United States cause opioid epidemic. There are no 31 effective treatments for opioid addiction. Researchers have some understanding 32 of the mechanism of opioid addiction at the molecular level, in relation to its pain-33 relieving effect in the brain, but there are still many issues to be addressed. We 34 developed a computational strategy in an effort to find novel target genes and 35 effective therapeutic treatment of opioid dependence and addiction. Using 36 statistical and machine learning methods, we identified genes and transcription 37 regulators that can serve as potential targets for treating opioid dependence and 38 addiction. Our results revealed both known and novel genes and transcription 39 regulators that were associated to dependence-related behavioral changes after 40 opioid administration. Moreover, we found that many behavioral changes after 41 opioid addiction are related to opioid effects on pain relief as well as immune and 42 neuronal signaling. Following our analysis, we further determined small 43 compounds that can potentially target dependence-associated genes and Introduction 48 Opioids such as morphine have long been used as mainstay therapy for treating 49 different types of chronic severe pains such as cancer pain, noncancer-related 50 pain, and neuropathic pain [1] . As a result of relaxation on restriction of prescription 51 opioids for treating chronic noncancer pain and promotion of opioids in treatment 52 by pharmaceutical industry, practitioners and many organizations, non-medical 53 use and abuse of prescription opioids has been increasing rapidly in the United 54
States [2] , which in turn leads to opioid epidemic [3] . 55 56 Despite that opioids have beneficial analgesic effects of alleviating acute and 57 chronic pain, chronic opioid use can lead to adverse side effects including 58 tolerance, hyperalgesia, withdrawal reactions, and even dependence [2, 4, 5] . In 59 order to achieve optimal pain management, many studies have been carried out 60 to elucidate mechanisms underlying both the beneficial as well as the adverse 61 effects of opioids. Plenty of evidence has shown that crosstalks between neuronal 62 signaling, immune responses and chemokines play significant roles in the pain 63 pathways responsive to opioids such as morphine, and these signaling networks 64 can lead to both behavioral and structural changes in the brain [6, 7] . 65
Studies on effects of opioids to relieve pain mainly focus on brain regions such as 67 periaqueductal gray, rostral ventromedial medulla, and dorsal root ganglia [6] , 68 while investigations of addictive effects of opioids mostly focus on striatum, since 69 striatum is a main component of the reward system responsible for drug 70 dependence and addiction. Striatum receives several types of neuronal inputs from 71 prefrontal cortex (PFC), ventral tegmental area (VTA), and other areas of the brain 72
[8], and over time, drug dependence and addiction can be reinforced [9] . At the 73 molecular level, many transcription factors (TFs) have been associated with 74 behaviors related to drug abuse and addiction. Some TFs known to play key roles 75 in drug addiction include ΔFosB, cyclic AMP-responsive element binding protein 76 (CREB), NF-κB, and MEF2 [7] . For instance, opioids can reduce Fos expression 77 in the direct pathway striatal neurons [ In order to treat opioid addiction, opioid antagonists such as naltrexone have been 100 used to treat opioid addiction for several decades. However, they have shown 101 limited efficacy in relapse prevention [18, 19] . Recently, alternative approaches 102 such as receptor-based therapeutic strategies have been proposed which aim to 103 target receptors including G protein-coupled receptors (GPCRs) such as μ-, δ-, 104 and κ-opioid receptors, chemokine receptors, as well as neuroimmune receptors 105 such as Toll-like receptors 4 (TLR4) [20] [21] [22] . However, despite all the efforts and 106 advances in understanding the mechanism of addiction in the past decades, they 107 have not led to development of effective new anti-addiction agents [23] . Therefore, 108 finding novel targets and strategies is needed for treating opioid dependence and 109 addiction. 110
111
In this work, we developed a new computational strategy for identification of novel 112 genome-wide targets and potential therapeutic treatments for opioid dependence. 113
In particular, this strategy involves first detecting genes and pathways induced by 114 either morphine or heroin which are associated with dependence, then 115 identification of small compounds which can target the dependence-associated 116 genes responsive to the opioids. Using this strategy, we identified morphine and 117 heroin-induced genes and pathways associated with dependence-related 118 behaviors such as physical dependence and psychological dependence, as well 119 as transcription regulators which can potentially regulate these genes. Finally, we 120 identified small compounds which can potentially target some of the dependence-121 related genes and transcription factors. A database for all the dependence 122 associated genes and transcription regulators, along with small compounds for 123 targeting those genes and transcription regulators, is available at 124 http://daportals.org. Our findings can facilitate identification of novel candidate 125 7 we found that 423 genes were differentially expressed (DE) after morphine 134 administration in mice, while 608 genes were differentially induced by heroin. 135
Using k-means clustering, we identified 6 expression patterns among genes 136 induced by each opioid (Figs 1 and 2) , with genes upregulated and downregulated 137 at 3 phases: Immediate-Early (IE), Middle (M), and Late (L), respectively. 138
Compared to morphine, heroin induced twice as many genes in the IE and L 139 phases, respectively (Figs 1 and 2), indicating that heroin elicits neurobiological 140 responses in mice not only faster but also longer lasting than morphine. Our GO and KEGG analyses revealed that many DEGs induced by either 155 morphine or heroin in the mouse striatum were involved in the immune and 156 neuronal processes and pathways (Tables 1 and 2, S1 and S2 Tables). Many of 157 these biological processes are previously known to play important roles in opioid-158 mediated pain pathways in brain regions such as dorsal root ganglia [6] . However, 159 despite that the neuroimmune signaling processes induced by either morphine or 160 heroin in mouse striatum share some similarities, it is also apparent that the two 161 opioids elicit distinct neurobiological responses in the animals which we will detail 162 below: 163 164 
Immune and neuronal responses to morphine in mouse striatum 181
Immune responses: Most genes involved in the immune system were induced by 182 morphine in the M phase. As shown in Table 1 , some genes participating in anti-183 inflammatory processes were responsive to morphine, e.g., genes involved in 184 negative regulation of NF-κB transcription factor activity were upregulated, and 185 those involved in MAPK pathway, humoral immune response, and induction of positive chemotaxis were downregulated. Since anti-inflammatory pathways are 187 known to play key roles in opioid-induced pain relief [6], these results are 188 consistent with the fact that morphine induces analgesia effect in animals. 189
190
On the other hand, some genes participating in proinflammatory responses were 191 also upregulated by morphine, including, e.g., genes involved in Toll-like receptor 192 signaling pathway, and activation of innate immune response. Notably, previous 193 evidence showed that proinflammatory responses play central roles which 194 contribute to tolerance during chronic opioid exposure [7] . Genes involved in 195 response to xenobiotic stimulus were also upregulated in the L phase, in line with 196 the fact that these genes are essential in sensing that the cells are under the 'insult' 197 of the drug. 198 199 Together, these results suggest that crosstalks between genes involved in 200 proinflammatory and anti-inflammatory pathways have already initiated in mouse 201 striatum during short-term morphine administration. 202 203 Neuronal responses: Our results also showed that genes participating in 204 neuronal responses were induced by morphine (Table 1) , which is not surprising, 205
given known neurological effects of morphine in the brain. For example, positive 206 regulation of autophagy and programmed cell death were upregulated in the IE 207 phase, and also genes involved in glutamatergic synaptic transmission, glutamate 208 receptor signaling pathway, and sensory organ development were all 209 downregulated in the M phase. Notably, all these neuronal signaling events have 210 been implicated in the analgesia induced by morphine (Table 1) , again supporting 211 the notion that morphine can induce analgesia in the treated mice. Also, genes 212 involved in cell projection morphogenesis were upregulated in the L phase, in line 213 with the evidence that morphine can induce structural changes in mice during 214 chronic exposure [33] . 215 216 Together, our results suggest that even during short-term morphine exposure, 217 complex crosstalks between genes involved in proinflammatory and anti-218 inflammatory pathways, neuronal signaling, and the chemokine system have 219 already initiated in mouse striatum, which can contribute to analgesia and/or 220 tolerance effects if exposure of the drug lasts longer. 221 222
Immune and neuronal responses to heroin in mouse striatum 223
Immune responses: Our results showed that distinct from morphine, many 224 immune genes induced by heroin were downregulated in the L phase (Table 2) Other key biological responses: Our results also showed that heroin induced 248 genes participating in other key biological processes involved in pain-related 249 pathways, e.g., genes involved in protein autophosphorylation are upregulated in 250 the IE phase. Since protein phosphorylation is known to play key roles in 251 desensitization and implicated in opioid-induced hyperalgesia [22], our results 252 suggest that these genes contribute to dependence induced by chronic use of 253 heroin; this speculation is confirmed by our association analysis described below. 254
drugs of abuse 257
In order to find out whether DEGs induced by either morphine or heroin are 258 associated with various harmful effects linked to drugs of abuse, we conducted the 259 association analysis between expression levels of morphine-or heroin-induced 260 In order to find out whether the dependence-associated DEGs induced by each 285 opioid were co-regulated by any TFs or epigenetic factors, we performed the TF 286 and epigenetic factor binding site enrichment test using the ENCODE ChIP-Seq 287 significance tool [44] . Our analysis showed that 17 transcription regulators 288 potentially modulated morphine-responsive dependence-associated DEGs (S6 289 Table) , while that 12 transcription regulators modulated heroin-responsive 290 dependence-associated DEGs (S7 Table) . More details about our results are 291 described below. 292 293
Transcription regulators detected after morphine exposure 294
Known TFs associated with dependence and addiction: More than half of the 295 TFs we detected regulating dependence-associated DEGs after morphine 296 exposure are previously known to play important roles in drug dependence and 297 addiction. For example, we found that MEF2A upregulated four DEGs which were 298 associated with physical dependence in the M phase, while that MEF2C 299 upregulated one DEG associated with dependence in the IE phase after morphine exposure, agreeing with the evidence that MEF2 is crucial in inducing behavioral 301 changes after exposure to drugs of abuse [7] . 302 303 Novel TFs induced by morphine: Our results also showed a few novel TFs 304 activated by morphine. In order to quantify the magnitude of the effects the 305 detected transcription regulators on the dependence-related behaviors induced by 306 the opioids, we developed a scoring metric, called dependence score, based on 307 the total fold changes of the dependence-associated DEGs co-regulated by each 308 regulator (see details in Methods). Using this approach, we found that E2f6, which 309 potentially regulated 13 DEGs associated with physical dependence after 310 morphine exposure, had the highest dependence score of 17.93. Also, we 311 detected ZBTB33 and ZKSCAN1 associated with physical dependence having 312 high dependence scores (11 and 6.8, respectively) after morphine exposure. In Table) . Literature search (S8 Table) suggests that these factors including 323 [5, 7]. Moreover, our results showed that Polr2a (encoding the largest subunit of 340 RNA polymerase II), EGR1, and CREB1 were associated with social and physical 341 harm with the highest scores (> 20), suggesting that these TFs play key roles in 342 the biological mechanism that underlies the higher social and physical harm 343 caused by heroin compared to other drugs of abuse [4] . 344 345 dependence score in morphine) also had the highest dependence score of 6.52, 347 potentially regulating four DEGs associated with psychological dependence after 348 exposure to heroin. 349 350 Epigenetic regulators: Similar to morphine, more than 40% of the detected 351 transcription regulators were epigenetic factors after heroin exposure (S7 Table) . and that epigenetic regulation plays major roles after exposure to both opioids. 360
Further investigation is needed to elucidate the roles of the novel TFs (e.g., E2F6) 361 with high dependence scores after exposure of either morphine or heroin. 362 363
Finding small compounds which can target the DEGs and the dependence-364 associated transcription regulators induced by the opioids 365
To facilitate development of therapeutic interventions for treating morphine or 366 heroin dependence, we developed a strategy which allowed us to identify small 367 compounds that can target the opioid-induced dependence-associated DEGs and 368 their potential transcription regulators (see details in Methods). Our results are 369 shown in S9 and S10 Tables for morphine and heroin, respectively. Among all the 370 small compounds we identified, we found that Calmidazolium could target 8 371 morphine-induced dependence-associated DEGs (S9A Table) , and that 372 Securinine could target E2F6 which had the highest dependence score after 373 morphine exposure (Table 3) . Also, we identified that Phenacetin and Buspirone 374 could target 11 and 4 heroin-induced dependence-associated DEGs, respectively 375 (Table 4 , S1 Fig) , and that Meclofenoxate could target E2F6 which had the highest 376 dependence score also after heroin exposure (S10B Table) . 377 378 379 In this study, we developed a computational strategy to identify candidate 403 dependence-associated DEGs induced by either morphine or heroin, as well as to 404 find small compounds which could target these genes for treating dependence of 405 the opioids. Using this strategy, we analyzed a time-course gene expression 406 microarray data set generated previously to investigate gene expression patterns 407 responsive to various drugs of abuse in mouse striatum [24] . In particular, we first 408 employed a local regression technique to detect genes differentially expressed 409 over 8 hours of time in mouse striatum after either morphine or heroin exposure. 410
Then, we performed correlation analysis to identify morphine or heroin-induced 411
DEGs which were associated with twelve harmful effects including dependence 412 commonly linked to drugs of abuse. Furthermore, we detected potential 413 transcription regulators including TFs and epigenetic factors that regulated the 414 dependence-associated DEGs using an ENCODE enrichment tool. Finally, to 415 facilitate the identification of candidate targets and development of effective therapy for morphine and heroin-induced dependence, we identified small 417 compounds which could potentially target against some of the detected 418 dependence-associated DEGs and transcription regulators. 419 420 Using the approach described above, we found that a significant number of the 421 DEGs responsive to either morphine or heroin in mouse striatum were involved in 422 the neuroimmune signaling pathways, which are typically activated in the pain-423 related pathways during chronic opioid use previously identified in other brain 424 areas including periaqueductal gray, rostral ventromedial medulla, and dorsal root 425 ganglia [6] . Using correlation analysis, we found that a considerable portion of the 426 pain pathway-related DEGs, previously known to play active roles in opioid 427 analgesia, tolerance, hyperalgesia, and allodynia, were associated with the 428 harmful effects (such as dependence) linked to morphine and heroin as well as 429 many other drugs of abuse, e.g., Irak1 (encoding interleukin-1 receptor-associated 430 kinase 1) in the enriched Toll-like receptor signaling pathway (Table 1) induced by 431 morphine was correlated with physical dependence at a nominal level of 432 significance (p < 0.05). Toll-like receptor signaling pathway has been known to 433 play crucial roles in proinflammatory signaling and tolerance to opioid analgesia. 434
We also noticed that some dependence-associated DEGs could be induced by 435 both morphine and heroin, e.g., among DEGs upregulated in the IE phase, Dapk1 436 and Plekhf1 were correlated with psychological dependence, while Dusp12 and 437
Pim3 were associated with physical dependence after exposure to both morphine 438 and heroin. It is unclear what roles these genes (induced by both opioids) play 439 when mice were first exposed to morphine, then switched to heroin later on, a 440 scenario commonly seen among human drug abusers. 441 442 Despite the similarities in gene expression responses induced by both morphine 443 and heroin in mouse striatum, differences between the two opioids are also 444 obvious. For example, a large number of the DEGs involved in immune signaling 445 were downregulated in the L phase after heroin exposure, as opposed to morphine 446 exposure, suggesting that heroin elicited strong anti-inflammatory responses in the 447 L phase and thus induced acute analgesic effects in the mice. 448
449
Among detected transcription regulators that potentially regulate the dependence-450 associated DEGs, MEF2A induced by morphine as well as EGR1 and CREB1 by 451 heroin are known to play crucial roles in drug addiction. We also found that more 452 than 40% of the detected transcription regulators are epigenetic factors after both 453 morphine and heroin exposure, including HDAC8 and HDAC6 activated by 454 morphine, which supports the previous notion that epigenetic factors are important 455 for addiction. Furthermore, using the dependence score, a metric we developed 456 for measuring the extent the detected transcription regulators affect the 457 dependence-associated DEGs, we found that E2F6 has the highest dependence 458 scores after exposure of both morphine and heroin. 459
460
In summary, our work here intent to elucidate molecular connections between the 461 analgesic and tolerance-related pain pathways and harmful side effects of opioid 462 use during pain treatment. Despite the general belief that morphine is safe for 463 managing patients with pain, our results suggest that morphine may induce 464 tolerance to analgesia and dependence on the drug in the patients in the very early 465 stage, which may increase the possibility of the same patients to abuse heroin 466 thereafter, since heroin may further induce acute analgesic effects as suggested 467 by our results. Moreover, because heroin can cause both structural and behavioral 468 changes among patients, abusing heroin after morphine may lead to more potent 469 dependence on the drugs among the patients. The limitations of our work include the following. The gene expression microarray 480 data we analyzed spanned only 8 hours after administration of morphine and 481 heroin, which limited our ability to discover chronic effects of the drugs. In the future 482 study, we intend to employ the same strategy to investigate long-term effects of 483 morphine and heroin, and to compare them with the acute effects we discovered 484 in this work. Also, biological validation is needed to verify our findings here. 485
Despite the limitations, we found that our results agree well with the previously 486 known evidence about drug abuse and addiction, suggesting our findings are valid 487 and worth further in-depth investigation. Moreover, our work provides insight into 488 the molecular connections between the opioid-induced pain-related pathways and 489 the adverse harmful effects associated with morphine and heroin. Understanding 490 such connections may facilitate development of effective therapies which allow 491 people to target dependence-associated genes and transcription regulators at an 492 early stage of opioid use while preserving analgesic effects of opioids. 493
Dataset 495
The gene expression microarray data set we analyzed in this work was obtained 496 from the NCBI Gene Expression Omnibus (GEO) database under the accession 497 number [GEO:GSE15774]. This data set was generated from a previous work 498 In order to identify temporal patterns for DEGs responsive to either morphine or 530 heroin exposure, we applied a k-means clustering algorithm proposed by Hartigan 531 and Wong [57] to the temporal expression values of the DEGs. The Euclidean 532 distance was used to measure dissimilarities between different genes. A thousand 533 iterations were performed to find an optimal partition of K clusters where K is pre-534 assigned. To determine an optimal number of the clusters for the DEGs, we 535 employed the average silhouette width (ASW) as described in [58] , and when K = 536 6, ASW is the largest for the DEGs induced by both morphine and heroin. 537 drugs of abuse were taken from Nutt et. al. [4] and can be found in S3 Table. In 553 particular, the scores for the harmful effects encompassing three categories, 554 including physical harm (overall, acute, chronic), dependence (pleasure, 555 psychological, physical), social harm (overall, health-care costs), and conditioned 556 place preference for the drugs including morphine, heroin, cocaine, 557 methamphetamine, ethanol, and nicotine were used to calculate the association of 558 each harmful effect and the DEGs induced by either morphine or heroin. Gi within phase P, relative to that of the control time point, and Gi is regulated by 599 R. The higher the dependence score, the more impact the transcription regulator 600 R can have on dependence. 601 602 Using a similar concept as the dependence score, we also assigned association 603 scores to transcription regulator R if the DEGs it regulates were also associated 604 with other harmful effects of drugs (as shown in S3 Table) . Specifically, an 605 association score between a transcription regulator R and a harmful effect H was 606 defined as the sum of the maximum absolute fold change of the DEGs regulated 607 by R in phase P that were associated with H. 608
609
Finding small molecular compounds to target the opioid-induced 610
dependence-associated DEGs and the transcription regulators 611
Gene expression patterns in cells can change during treatment by small-molecule 612 drugs or compounds [60] . If a small compound has an opposite effect on 613 transcription than opioids, the small compound has potential to reverse the gene 614 signature induced by opioids and hence the subsequent harmful effects caused by 615 opioids. With the availability of gene expression profiles of small molecular 616 compounds, we were able to compare them with those of morphine and heroin, 617 and identify small compounds with the potential for treating dependence and 618 addiction induced by each opioid. 619 620 Specifically, we employed the following two-step strategy to find the small 621 compounds: 622 
